A randomized, double-blind, cross-over placebo-controlled trial found that simvastatin, with or without the addition of ezetimibe, can reduce the levels of IFN-γ and MCP-1 in patients with diabetes and chronic kidney disease, but not in patients who had only diabetes [108]. This evidence concerns the gene CCL2 and diabetes mellitus.